心绞痛和急性心肌梗死患者血清血管内皮生长因子水平

Serum levels of vascular endothelial growth factor in patients with angina pectoris and acute myocardial infarction.

作者信息

Yin R, Feng J, Chen D, Wu H

机构信息

Guangdong Provincial Cardiovascular Institute, Guangzhou 510100.

出版信息

Chin Med Sci J. 2000 Dec;15(4):205-9.

PMID:12906138

Abstract

OBJECTIVE

To determine whether serum vascular endothelial growth factor (VEGF) concentrations are altered in several kinds of coronary heart disease patients.

MATERIALS AND METHODS

Using a VEGF enzyme-linked immunosorbent assay (ELISA), serum VEGF concentrations were determined in antecubital venous blood of 16 patients with stable angina pectoris (SAP), 16 with unstable angina pectoris (UAP) and 16 with acute myocardial infarction (AMI) before and after thrombolytic therapy, and of 16 age- and sex-matched healthy volunteers who used as controls.

RESULTS

The concentrations of serum VEGF in patients with SAP (98.60 +/- 26.99 pg/ml) and UAP (103.61 +/- 24.89 pg/ml) tended to be higher than those in control subjects (80.44 +/- 24.57 pg/ml), but the differences did not reach statistical significance (P > 0.05 for each). Before thrombolytic therapy, the concentrations of serum VEGF in patients with AMI (285.92 +/- 125.15 pg/ml) were significantly higher than those in patients with SAP, UAP or control subjects (P < 0.01, respectively), and correlated with synchronous serum creatine kinase (CK) and its MB isoenzyme (CK-MB) contents (r = 0.866, P < 0.001 and r = 0.948, P < 0.001; respectively). Three hours after thrombolysis, the concentrations of VEGF had fallen to 111.57 +/- 31.29 pg/ml (P < 0.01 vs x before thrombolytic therapy and P < 0.05 vs x control subjects).

CONCLUSION

The present study shows that serum concentrations of VEGF in patients with AMI are markedly elevated and that increased serum VEGF levels may be one of the most sensitive indexes in diagnosing AMI and judging reperfusion.

摘要

目的

确定几种冠心病患者血清血管内皮生长因子（VEGF）浓度是否发生改变。

材料与方法

采用VEGF酶联免疫吸附测定（ELISA）法，测定16例稳定型心绞痛（SAP）患者、16例不稳定型心绞痛（UAP）患者和16例急性心肌梗死（AMI）患者溶栓治疗前后肘前静脉血中的血清VEGF浓度，并测定16例年龄和性别匹配的健康志愿者作为对照。

结果

SAP患者（98.60±26.99 pg/ml）和UAP患者（103.61±24.89 pg/ml）的血清VEGF浓度倾向于高于对照组（80.44±24.57 pg/ml），但差异无统计学意义（每组P>0.05）。溶栓治疗前，AMI患者的血清VEGF浓度（285.92±125.15 pg/ml）显著高于SAP患者、UAP患者或对照组（分别为P<0.01），并与同步血清肌酸激酶（CK）及其MB同工酶（CK-MB）含量相关（r=0.866，P<0.001；r=0.948，P<0.001）。溶栓后3小时，VEGF浓度降至111.57±31.29 pg/ml（与溶栓治疗前相比P<0.01，与对照组相比P<0.05）。